Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
58.38 (1y: +29%)
Market Cap 72.47 B P/E(ttm) 18.20
Enterprise Value 80.97 B P/B 1.90
CVS- NYSE (USA)
CVS Caremark Corp
  • Currently 3.5/5
Business Predictability Rank: 3.5-Star
Back Testing Results:
Average gain of all 3.5-Star stocks: 9.3% per year.
% of Stocks that are in still loss if held for 10yrs: 9%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$58.38
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry		 vs
history
Cash to Debt 0.14
CVS's Cash to Debt is ranked lower than
82% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.55 vs. CVS: 0.14 )
CVS' s 10-Year Cash to Debt Range
Min: 0.1   Max: 0.78
Current: 0.14
0.1
0.78
Equity to Asset 0.024
CVS's Equity to Asset is ranked lower than
90% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.34 vs. CVS: 0.024 )
CVS' s 10-Year Equity to Asset Range
Min: -0.06   Max: 0.45
Current: 0.02
-0.06
0.45
Interest Coverage 13
CVS's Interest Coverage is ranked lower than
59% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 41.95 vs. CVS: 13 )
CVS' s 10-Year Interest Coverage Range
Min: 7   Max: 25
Current: 13
7
25
F-Score: 7
Z-Score: 4.4
M-Score: -2.58
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry		 vs
history
Operating margin (%) 5.90
CVS's Operating margin (%) is ranked higher than
83% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.80 vs. CVS: 5.90 )
CVS' s 10-Year Operating margin (%) Range
Min: 1.3   Max: 6.9
Current: 5.9
1.3
6.9
Net-margin (%) 3.1
CVS's Net-margin (%) is ranked higher than
77% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.50 vs. CVS: 3.1 )
CVS' s 10-Year Net-margin (%) Range
Min: 1.9   Max: 3.7
Current: 3.1
1.9
3.7
ROE (%) 10.3
CVS's ROE (%) is ranked higher than
61% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 8.80 vs. CVS: 10.3 )
CVS' s 10-Year ROE (%) Range
Min: 8.4   Max: 17.3
Current: 10.3
8.4
17.3
ROA (%) 5.9
CVS's ROA (%) is ranked higher than
76% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.20 vs. CVS: 5.9 )
CVS' s 10-Year ROA (%) Range
Min: 4.8   Max: 9.4
Current: 5.9
4.8
9.4
ROC (Joel Greenblatt) (%) 51.60
CVS's ROC (Joel Greenblatt) (%) is ranked higher than
86% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 16.00 vs. CVS: 51.60 )
CVS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 6.8   Max: 51.6
Current: 51.6
6.8
51.6
Revenue Growth (%) 9
CVS's Revenue Growth (%) is ranked higher than
91% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.20 vs. CVS: 9 )
CVS' s 10-Year Revenue Growth (%) Range
Min: 5.9   Max: 12
Current: 9
5.9
12
EBITDA Growth (%) 6.8
CVS's EBITDA Growth (%) is ranked higher than
83% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.25 vs. CVS: 6.8 )
CVS' s 10-Year EBITDA Growth (%) Range
Min: -19.3   Max: 45.1
Current: 6.8
-19.3
45.1
EPS Growth (%) 4.4
CVS's EPS Growth (%) is ranked higher than
81% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 7.70 vs. CVS: 4.4 )
CVS' s 10-Year EPS Growth (%) Range
Min: 3   Max: 21.8
Current: 4.4
3
21.8
» CVS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

CVS Guru Trades in Q2 2012

Jim Simons 260,105 sh (New)
Ken Fisher 4,406 sh (New)
Joel Greenblatt 37,199 sh (+56.43%)
Pioneer Investments 2,824,963 sh (+4.83%)
RS Investment Management 1,193,125 sh (+2.48%)
Mario Gabelli 1,665,442 sh (+0.48%)
First Pacific Advisors 8,122,900 sh (+0.29%)
Steven Romick 7,495,000 sh (unchged)
Westport Asset Management 192,090 sh (unchged)
Vanguard Health Care Fund 300,000 sh (unchged)
Charles de Vaulx 1,148,050 sh (unchged)
Lee Ainslie Sold Out
Wallace Weitz 962,970 sh (-0.01%)
NWQ Managers 6,346,190 sh (-1.95%)
James Barrow 6,258,216 sh (-2.33%)
Jeremy Grantham 627,231 sh (-2.55%)
Ruane Cunniff 30,999 sh (-6.78%)
Chris Davis 61,954,182 sh (-7.39%)
HOTCHKIS & WILEY 3,815,900 sh (-8.32%)
Jeff Auxier 102,672 sh (-11.28%)
Warren Buffett 5,301,916 sh (-25.39%)
PRIMECAP Management 543,000 sh (-39.93%)
Leon Cooperman 596,955 sh (-68.42%)
Steven Cohen 50,341 sh (-73.2%)
» More
Q3 2012

CVS Guru Trades in Q3 2012

Paul Tudor Jones 6,100 sh (New)
Ray Dalio 55,646 sh (New)
John Hussman 1,000,000 sh (New)
Ken Fisher 212,344 sh (+4719.43%)
Pioneer Investments 4,329,866 sh (+53.27%)
Jeremy Grantham 698,834 sh (+11.42%)
Mario Gabelli 1,673,862 sh (+0.51%)
Vanguard Health Care Fund 300,000 sh (unchged)
Westport Asset Management 192,090 sh (unchged)
Warren Buffett Sold Out
Jim Simons Sold Out
HOTCHKIS & WILEY 3,795,300 sh (-0.54%)
Jeff Auxier 100,922 sh (-1.7%)
Signature Select Canadian Fund 182,753 sh (-1.72%)
Joel Greenblatt 35,859 sh (-3.6%)
Steven Romick 7,185,000 sh (-4.14%)
First Pacific Advisors 7,782,900 sh (-4.19%)
Chris Davis 58,546,339 sh (-5.5%)
Wallace Weitz 863,960 sh (-10.28%)
Charles de Vaulx 1,027,406 sh (-10.51%)
Ruane Cunniff 26,255 sh (-15.3%)
NWQ Managers 4,887,372 sh (-22.99%)
RS Investment Management 697,225 sh (-41.56%)
James Barrow 984,300 sh (-84.27%)
Leon Cooperman 56,000 sh (-90.62%)
PRIMECAP Management 21,000 sh (-96.13%)
Steven Cohen 1,718 sh (-96.59%)
» More
Q4 2012

CVS Guru Trades in Q4 2012

Scott Black 172,675 sh (New)
Jim Simons 2,048,005 sh (New)
Paul Tudor Jones 253,700 sh (+4059.02%)
Steven Cohen 54,325 sh (+3062.11%)
Ray Dalio 612,946 sh (+1001.51%)
Joel Greenblatt 86,763 sh (+141.96%)
Pioneer Investments 4,664,581 sh (+7.73%)
RS Investment Management 745,625 sh (+6.94%)
Vanguard Health Care Fund 300,000 sh (unchged)
PRIMECAP Management 21,000 sh (unchged)
Ruane Cunniff 26,255 sh (unchged)
Westport Asset Management 192,090 sh (unchged)
Jeremy Grantham 2,029,128 sh (unchged)
Leon Cooperman Sold Out
Jeff Auxier 99,772 sh (-1.14%)
HOTCHKIS & WILEY 3,652,600 sh (-3.76%)
James Barrow 940,895 sh (-4.41%)
Wallace Weitz 823,960 sh (-4.63%)
Steven Romick 6,805,000 sh (-5.29%)
Mario Gabelli 1,584,062 sh (-5.36%)
Charles de Vaulx 961,113 sh (-6.45%)
First Pacific Advisors 7,222,500 sh (-7.2%)
NWQ Managers 4,232,538 sh (-13.4%)
Chris Davis 49,038,267 sh (-16.24%)
Ken Fisher 166,847 sh (-21.43%)
John Hussman 250,000 sh (-75%)
» More
Q1 2013

CVS Guru Trades in Q1 2013

Bruce Kovner 65,000 sh (New)
Vanguard Health Care Fund 1,699,800 sh (+466.6%)
Jeremy Grantham 2,483,088 sh (+22.37%)
Mario Gabelli 1,633,662 sh (+3.13%)
First Pacific Advisors 7,325,600 sh (+1.43%)
Jeff Auxier 100,522 sh (+0.75%)
Scott Black 173,533 sh (+0.5%)
Westport Asset Management 192,090 sh (unchged)
Steven Romick 6,805,000 sh (unchged)
PRIMECAP Management 21,000 sh (unchged)
John Hussman Sold Out
Ruane Cunniff 26,155 sh (-0.38%)
RS Investment Management 741,625 sh (-0.54%)
Ken Fisher 163,139 sh (-2.22%)
NWQ Managers 3,882,362 sh (-8.27%)
Pioneer Investments 4,213,730 sh (-9.67%)
Chris Davis 42,927,207 sh (-12.46%)
HOTCHKIS & WILEY 2,846,700 sh (-22.06%)
James Barrow 686,895 sh (-27%)
Joel Greenblatt 60,144 sh (-30.68%)
Wallace Weitz 557,700 sh (-32.31%)
Ray Dalio 340,450 sh (-44.46%)
Jim Simons 1,047,905 sh (-48.83%)
Steven Cohen 5,760 sh (-89.4%)
Paul Tudor Jones 5,100 sh (-97.99%)
» More
» Details

Insider Trades

Latest Guru Trades with CVS

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Wallace Weitz 2013-03-31 Reduce -32.31%0.58%$48.35 - $55.3 $ 58.713%557700
John Hussman 2013-03-31 Sold Out 0.32%$48.35 - $55.3 $ 58.713%0
Vanguard Health Care Fund 2013-03-31 Add 466.6%0.3%$48.35 - $55.3 $ 58.713%1699800
Ray Dalio 2013-03-31 Reduce -44.46%0.13%$48.35 - $55.3 $ 58.713%340450
Joel Greenblatt 2013-03-31 Reduce -30.68%0.07%$48.35 - $55.3 $ 58.713%60144
James Barrow 2013-03-31 Reduce -27%0.02%$48.35 - $55.3 $ 58.713%686895
Scott Black 2012-12-31 New Buy1.2%$44.7 - $49.24 $ 58.725%172675
John Hussman 2012-12-31 Reduce -75%0.9%$44.7 - $49.24 $ 58.725%250000
Ray Dalio 2012-12-31 Add 1001.51%0.27%$44.7 - $49.24 $ 58.725%612946
Joel Greenblatt 2012-12-31 Add 141.96%0.14%$44.7 - $49.24 $ 58.725%86763
Leon Cooperman 2012-12-31 Sold Out 0.05%$44.7 - $49.24 $ 58.725%0
John Hussman 2012-09-30 New Buy1.2%$43.99 - $48.59 $ 58.727%1000000
Leon Cooperman 2012-09-30 Reduce -90.62%0.57%$43.99 - $48.59 $ 58.727%56000
James Barrow 2012-09-30 Reduce -84.27%0.51%$43.99 - $48.59 $ 58.727%984300
Warren Buffett 2012-09-30 Sold Out 0.33%$43.99 - $48.59 $ 58.727%0
PRIMECAP Management 2012-09-30 Reduce -96.13%0.04%$43.99 - $48.59 $ 58.727%21000
Ray Dalio 2012-09-30 New Buy0.04%$43.99 - $48.59 $ 58.727%55646
Lee Ainslie 2012-06-30 Sold Out 3.1%$43.14 - $46.49 $ 58.731%0
Leon Cooperman 2012-06-30 Reduce -68.42%1.16%$43.14 - $46.49 $ 58.731%596955
Warren Buffett 2012-06-30 Reduce -25.39%0.11%$43.14 - $46.49 $ 58.731%5301916
Joel Greenblatt 2012-06-30 Add 56.43%0.05%$43.14 - $46.49 $ 58.731%37199
PRIMECAP Management 2012-06-30 Reduce -39.93%0.02%$43.14 - $46.49 $ 58.731%543000
Premium More recent guru trades are included for Premium Members only!!

Top Ranked Articles about CVS Caremark Corp

Scott Black's Top Fourth Quarter New Buys
January 31, 2013
Scott Black - Scott Black's Top Fourth Quarter New Buys
Scott Black founded Delphi Management in 1978 on value investing precepts, emphasizing the fundamental performance of companies over the long term. He is known for contacting the management of every company that is a prospect for investment before committing capital. Read more...
Weekly Top Insider Buys: CVS, LTD, BBY, SFD, FNFG
October 8, 2012
According to GuruFocus Insider Data, these are the largest insider buys during the past week: CVS Caremark Corporation (CVS), Limited Brands Inc. (LTD), Best Buy Co. Inc. (BBY)., Smithfield Foods Inc. (SFD) and First Niagara Financial Group Inc. (FNFG). Read more...
Large-Cap Stocks No Longer Undervalued
September 18, 2012
- Large-Cap Stocks No Longer Undervalued
Last year, many investors were interested in mega-cap stocks, as they seemed to be undervalued. For instance, FPA Funds’ Steven Romick went on WealthTrack with Consuelo Mack in July 2011 to discuss why CVS (CVS), Walmart (WMT) and Microsoft (MSFT) were cheap at the time. However, the picture for these and many high-quality, big-market-cap stocks has changed, and they may have become not as good bargains as they once were. Just three mega-cap stocks currently have single-digit P/E ratios. Here are some large caps whose valuations have become less attractive recently. Read more...
Q&A with Investor Steven Romick of FPA Funds
August 28, 2012
Steven Romick - Q&A With Investor Steven Romick Of FPA Funds
Top investor Steven Romick will join GuruFocus for an interview this month. You can ask him a question related to investing by leaving it as a comment below. GuruFocus will receive his answers via a phone interview in the next several weeks. Read more...
Weekly Top Insider Buys: CVS, CHK, HRB, OI, SFD
July 16, 2012
According to GuruFocus Insider Data, these are the largest insider buys during the past week: CVS Caremark Corporation (CVS), Chesapeake Energy Corp. (CHK), H&R Block Inc. (HRB), Owens-Illinois Inc. (OI), and Smithfield Foods Inc. (SFD). Read more...
Going Back to Fundamentals (3): Debt to Equity
June 14, 2012
- Going Back To Fundamentals (3): Debt To Equity
In what might be considered by some as the simplest of criteria to evaluate, I have found that the debt to equity ratio actually can be very difficult or at best, time consuming. Why? Because once again, it’s just a number, and it means nothing unless you compare it with peers in the same industry and delve deeper into some hidden meanings behind the number. Let me explain. Read more...
Going Back to Fundamentals (2): ROA
June 7, 2012
- Going Back To Fundamentals (2): ROA
In the first part of this series, I discussed the current ratio. These discussions, once again, are an attempt to induce the investor to really consider all the facets of each criterion or metric they are considering. Numbers are just that… numbers. But without genuinely thinking about what those numbers actually mean to the investor, they become mechanical and eventually somewhat worthless. Read more...

Ratios

vs
industry		 vs
history
P/E(ttm) 18.30
CVS's P/E(ttm) is ranked higher than
75% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 16.24 vs. CVS: 18.30 )
CVS' s 10-Year P/E(ttm) Range
Min: 10.58   Max: 40.34
Current: 18.3
10.58
40.34
P/B 1.92
CVS's P/B is ranked lower than
55% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.51 vs. CVS: 1.92 )
CVS' s 10-Year P/B Range
Min: 0.85   Max: 5.87
Current: 1.92
0.85
5.87
P/S 0.60
CVS's P/S is ranked lower than
68% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.30 vs. CVS: 0.60 )
CVS' s 10-Year P/S Range
Min: 0.38   Max: 1.25
Current: 0.6
0.38
1.25
PFCF 20.74
CVS's PFCF is ranked lower than
55% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 14.04 vs. CVS: 20.74 )
CVS' s 10-Year PFCF Range
Min: 9.1   Max: 2171.9
Current: 20.74
9.1
2171.9
EV-to-EBIT 10.76
CVS's EV-to-EBIT is ranked higher than
84% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 11.60 vs. CVS: 10.76 )
CVS' s 10-Year EV-to-EBIT Range
Min: 7.6   Max: 48
Current: 10.76
7.6
48
PEG 2.29
CVS's PEG is ranked higher than
90% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.20 vs. CVS: 2.29 )
CVS' s 10-Year PEG Range
Min: 0.3   Max: 22.35
Current: 2.29
0.3
22.35
Shiller P/E 22.03
CVS's Shiller P/E is ranked higher than
81% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 14.98 vs. CVS: 22.03 )
CVS' s 10-Year Shiller P/E Range
Min: 13.82   Max: 32.57
Current: 22.03
13.82
32.57

Dividend & Buy Back

vs
industry		 vs
history
Dividend Yield 1.32
CVS's Dividend Yield is ranked higher than
52% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.82 vs. CVS: 1.32 )
CVS' s 10-Year Dividend Yield Range
Min: 0.38   Max: 1.39
Current: 1.32
0.38
1.39
Dividend Payout 0.3
CVS's Dividend Payout is ranked higher than
88% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.52 vs. CVS: 0.3 )
CVS' s 10-Year Dividend Payout Range
Min: 0.1   Max: 0.23
Current: 0.3
0.1
0.23
Dividend growth (3y) 20.8
CVS's Dividend growth (3y) is ranked higher than
98% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.70 vs. CVS: 20.8 )
CVS' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 20.8
Current: 20.8
0
20.8
Yield on cost (5-Year) 4.19
CVS's Yield on cost (5-Year) is ranked higher than
91% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.91 vs. CVS: 4.19 )
CVS' s 10-Year Yield on cost (5-Year) Range
Min: 1.23   Max: 4.48
Current: 4.19
1.23
4.48
Share Buyback Rate 3.1
CVS's Share Buyback Rate is ranked higher than
91% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: -0.30 vs. CVS: 3.1 )
CVS' s 10-Year Share Buyback Rate Range
Min: 3.1   Max: -14.9
Current: 3.1

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 7.1
CVS's Price/Net Current Asset Value is ranked higher than
85% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.75 vs. CVS: 7.1 )
CVS' s 10-Year Price/Net Current Asset Value Range
Min: 3.7   Max: 10.2
Current: 7.1
3.7
10.2
Price/Tangible Book 46.2
CVS's Price/Tangible Book is ranked higher than
100% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.10 vs. CVS: 46.2 )
CVS' s 10-Year Price/Tangible Book Range
Min: 2.6   Max: 39.6
Current: 46.2
2.6
39.6
Price/DCF (Projected) 1.1
CVS's Price/DCF (Projected) is ranked higher than
90% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.95 vs. CVS: 1.1 )
CVS' s 10-Year Price/DCF (Projected) Range
Min: 0.9   Max: 3.8
Current: 1.1
0.9
3.8
Price/Median PS Value 1.1
CVS's Price/Median PS Value is ranked higher than
84% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.95 vs. CVS: 1.1 )
CVS' s 10-Year Price/Median PS Value Range
Min: 0.7   Max: 2.1
Current: 1.1
0.7
2.1
Price/Peter Lynch Fair Value 2.3
CVS's Price/Peter Lynch Fair Value is ranked higher than
96% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.45 vs. CVS: 2.3 )
CVS' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.5   Max: 2.5
Current: 2.3
0.5
2.5
Price/Graham Number 6.2
CVS's Price/Graham Number is ranked higher than
100% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.45 vs. CVS: 6.2 )
CVS' s 10-Year Price/Graham Number Range
Min: 1.3   Max: 5.3
Current: 6.2
1.3
5.3
Earnings Yield (Greenblatt) 9.30
CVS's Earnings Yield (Greenblatt) is ranked higher than
89% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9.30 vs. CVS: 9.30 )
CVS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.1   Max: 13.1
Current: 9.3
2.1
13.1
Forward Rate of Return (Yacktman) 11.09
CVS's Forward Rate of Return (Yacktman) is ranked higher than
87% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 10.33 vs. CVS: 11.09 )
CVS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -11.6   Max: 42.3
Current: 11.09
-11.6
42.3

Business Description

CVS Caremark Corporation was incorporated in the State of Delaware. The Company is the pharmacy health care provider in the United States. It has three reportable business segments: Pharmacy Services, Retail Pharmacy and Corporate. The Pharmacy Services segment provides a full range of pharmacy benefit management ("PBM") services including mail order pharmacy services, specialty pharmacy services, plan design and administration, formulary management and claims processing. Its clients are primarily employers, insurance companies, unions, government employee groups, managed care organizations and other sponsors of health benefit plans and individuals throughout the United States. In addition, through its SilverScript Insurance Company ("SilverScript") and Accendo Insurance Company ("Accendo") subsidiaries, it is a national provider of drug benefits to eligible beneficiaries under the Federal Government's Medicare Part D program. Currently, the pharmacy services business operates under the Caremark Pharmacy Services, Caremark, CVS Caremark, CarePlus CVS/pharmacy, CarePlus, RxAmerica, AccordantCare and TheraCom names. As of December 31, 2011, the Pharmacy Services segment operated 31 retail specialty pharmacy stores, 12 specialty mail order pharmacies and four mail service pharmacies located in 22 states, the District of Columbia and Puerto Rico. The PBM services it provides for its clients involve the design and administration of programs aimed at reducing the cost and improving the safety, effectiveness and convenience of prescription drug use. These Services are Plan Design and Administration, Formulary Management, Discounted Drug Purchase Arrangements, Prescription Management Systems, Mail Pharmacy Program, Specialty Pharmacy, Onsite Pharmacies, Retail Pharmacy Network, Medicare Part D Service, Clinical Services, Disease Management Programs, Quality Assurance and Pharmacogenomic Services. It currently operates multiple information systems platforms to support its Pharmacy Services segment. These information systems incorporate architecture that centralizes the data generated from filling mail service prescriptions, adjudicating retail pharmacy claims and fulfilling other PBM clients' service contracts. It provides pharmaceuticals to eligible members in benefit plans maintained by its clients and utilize its information systems to perform safety checks, drug interaction screening and generic substitution.The Pharmacy Services segment competes with a number of large, national PBM companies, including Medco Health Solutions, Inc. and Express Scripts, Inc., as well as many smaller local or regional PBMs. As of December 31, 2011, the Retail Pharmacy segment included 7,327 retail drugstores, of which 7,271 operated a pharmacy, its online retail pharmacy website, CVS.com, 30 onsite pharmacy stores and its retail health care clinics. Its corporate segment provides management and administrative services to support the overall operations o
Company Website
SEC Reports
Industry: Pharmaceutical Retailers
Compare:SHDMF, APNHF, GNC, JCOUF, PMC
Traded in other countries:CVS.Germany
» More Articles for CVS

Headlines

Articles On GuruFocus.com
Walgreen Co. (WAG) Dividend Stock Analysis Apr 05 2013 
Chris Davis' Davis New York Venure Fund 2013 Annual Commentary Mar 08 2013 
Early Movers for Feb. 6, 2013 Feb 06 2013 
Delphi Management's Scott Black Releases Fourth Quarter New Stocks Jan 31 2013 
Dividend Contenders in Value for the Accumulation or Income Distribution Phase of the Retirement Por Jan 30 2013 
Steven Romick’s Top Growth Predictable Stocks Jan 22 2013 
My 4 Favorites from the 20 Most Recommended Dividend Stocks at All-Time Highs Jan 19 2013 
My 3 Favorites from the 20 Best Recommended Services Dividend Stocks Jan 12 2013 
Why Is Leon Cooperman Shopping in Walgreen’s? Dec 16 2012 
Tesco to Close or Sell U.S. Stores; Will Warren Buffett Buy More? Dec 05 2012 

More From Our Partners
Stock Market News for May 21, 2013 - Market News May 21 2013 - ZACKS

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial